
After the Danish government announced plans to support Bavarian Nordic’s vaccine candidate with DKK 800m (USD 128m) in financial aid in mid-August, the company's share price has gone up by 33 percent. The company has therefore cemented its place as the C25 index's winning stock this year with returns of about 85 percent, writes Danish business daily Børsen.
On Wednesday, the state funding was followed by positive results from Bavarian Nordic's RSV vaccine candidate. On Thursday, the company was rewarded by analysts raising the share price target.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app